SynthesisThe Cochrane database of systematic reviews2020
Pharmacological treatment of depression in people with a primary brain tumour.
Synthesis in The Cochrane database of systematic reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- JPOS/JASCC clinical guidelines for psychological distress in adult cancer patients: a summary of recommendations.Japanese journal of clinical oncology · 2026Guideline
- Recognizing the psychological impact of a glioma diagnosis on mental and behavioral health: a systematic review of what neurosurgeons need to know.Journal of neurosurgery · 2023Pooled it
- Palliative care and end-of-life care in adults with malignant brain tumors.Neuro-oncology · 2023Pooled it
- Cyclodextrin-Based Formulations as a Promising Strategy to Overcome the Blood-Brain Barrier: Historical Overview and Prospects in Glioblastoma Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Symptom management in isocitrate dehydrogenase mutant glioma.Neuro-oncology practice · 2025Review
- An Overview of Reviews on Predictors of Neurorehabilitation in Surgical or Non-Surgical Patients with Brain Tumours.Life (Basel, Switzerland) · 2024Review
- [Rational treatment of depressive syndromes in brain tumor patients].Der Nervenarzt · 2024Review
- Palliative Care in Neuro-oncology: an Update.Current neurology and neuroscience reports · 2023Review
- Patterns and predictors of anxiety and depression symptom trajectories in patients diagnosed with primary brain tumors.Journal of neuro-oncology · 2023Article
- Depression and anxiety in glioma patients.Neuro-oncology practice · 2023Review
- Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: A longitudinal study spanning two decades.Neuro-oncology · 2023Article
- A protocol for a pooled analysis of cohort studies: The association between depression and anxiety in epileptic disorders.PloS one · 2023Article
- Article
- A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer.Brain, behavior, & immunity - health · 2022Review
- Article
- Easing the Journey-an Updated Review of Palliative Care for the Patient with High-Grade Glioma.Current oncology reports · 2022Review
- Levetiracetam Prophylaxis Therapy for Brain Tumor-Related Epilepsy (BTRE) Is Associated With a Higher Psychiatric Burden.Frontiers in neurology · 2021Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis is the second updated version of the Cochrane Review published in Issue 3, 2010 and first updated in Issue 5, 2013. People with a primary brain tumour often experience depression, for which drug treatment may be prescribed. However, they are also at high risk of epileptic seizures, cognitive impairment, and fatigue, all of which are potential adverse side effects of antidepressants. The benefit, or harm, of pharmacological treatment of depression in people with a primary brain tumour is unclear.
objectivesTo assess the benefits and harms of pharmacological treatment of depression in people with a primary brain tumour. SEARCH
methodsWe updated the search to include CENTRAL, MEDLINE, Embase, and PsycINFO to September 2019. As in the original review, we also handsearched Neuro-Oncology, Journal of Neuro-Oncology, Journal of Neurology, Neurosurgery and Psychiatry, and Journal of Clinical Oncology: for the current update we handsearched the latest three years of articles from these journals (up to November 2019). SELECTION CRITERIA: We searched for all randomised controlled trials (RCTs), controlled clinical trials, cohort studies, and case-control studies of any pharmacological treatment of depression in people with a histologically diagnosed primary brain tumour. DATA COLLECTION AND ANALYSIS: No studies met the inclusion criteria. MAIN
resultsWe found no eligible studies evaluating the benefits of any pharmacological treatment of depression in people with a primary brain tumour. AUTHORS'
conclusionsWe identified no high-quality studies that investigated the value of pharmacological treatment of depression in people with a primary brain tumour. RCTs and detailed prospective studies are required to inform the effective pharmacological treatment of this common and important complication of brain tumours. Since the last version of this review none of the related new literature has provided additional information to change these conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.